Sarepta Therapeutics Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -7.2% | +54.9% | +208.4% | +25.5% | +11.0% | +63.7% | +5.5% | -0.6% | +4.4% | +21.4% | -15.5% | |
| – | -9.4% | +66.3% | +229.0% | +16.1% | +3.0% | +69.2% | +4.8% | -1.8% | +0.8% | +19.2% | -17.4% | |
| – | +9.2% | +52.4% | +389.9% | -38.2% | +125.2% | +79.9% | +40.8% | -54.3% | -55.7% | +157.5% | -27.4% | |
| – | -8.5% | +65.1% | +239.5% | +8.8% | -4.2% | +72.4% | +9.1% | -6.0% | -15.7% | -19.2% | -30.6% | |
| – | +64.6% | +31.5% | +463.7% | +66.4% | +91.5% | +47.5% | +23.9% | +52.4% | +67.0% | +48.7% | -20.0% | |
| – | -19.7% | -52.3% | +552.5% | +50.0% | +36.6% | +35.3% | -19.7% | +9.5% | +58.3% | +132.3% | +22.0% | |
| – | -3.0% | +1.2% | +14.2% | +124.8% | +33.6% | +46.9% | +0.4% | +28.2% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +12.7% | +21.6% | +77.7% | -19.4% | +8.0% | +9.1% | +4.5% | -46.8% | +290.9% | -9.2% | +7.7% | |
| – | +76.1% | +4.8% | +493.4% | +17.6% | +64.7% | +121.3% | -0.1% | +23.6% | -12.3% | +1.3% | -9.3% | |
| – | +69.0% | +21.1% | +17.1% | +96.6% | +52.4% | +57.1% | +8.8% | +36.9% | +5.5% | +11.9% | +49.7% | |
| – | +225.4% | +19.9% | -38.9% | +2,071.6% | -94.1% | +2,366.9% | +40.4% | -94.3% | +696.2% | -89.1% | -15.4% | |
| – | +63.1% | +46.7% | -71.5% | +299.5% | +101.3% | +63.1% | -30.9% | +24.9% | +72.0% | +30.0% | +31.0% | |
| – | +300.5% | -59.6% | +6,932.0% | -1.0% | +62.1% | +45.5% | +10.5% | +40.8% | -26.7% | +0.4% | -27.1% | |
| – | -23.1% | +76.9% | +134.4% | +30.8% | -20.7% | -6.9% | +21.8% | -58.5% | +123.2% | +77.8% | -25.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +5.7% | +15.2% | +20.8% | +12.6% | +11.1% | +5.9% | +4.2% | +7.7% | +5.5% | +16.8% | -2.9% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.